ALHC Form 4: Officer sells 15,491 shares at $16 average price

Q: How many ALHC shares did Christopher J. Joyce sell?

He sold 15,491 common shares on 31 Jul 2025.

Q: At what price were the ALHC shares sold?

The weighted-average sale price was $16.0061 per share, within a $16.00-$16.01 range.

Q: Does Joyce still hold ALHC stock after the sale?

Yes. He directly owns 374,531 shares following the transaction.

[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

On 31 Jul 2025, Alignment Healthcare (ALHC) Chief Legal & Administrative Officer Christopher J. Joyce filed a Form 4 disclosing the sale of 15,491 common shares at a weighted-average price of $16.0061 (range $16.00-$16.01). The trade was executed under a pre-arranged Rule 10b5-1 plan adopted 27 Nov 2024 and coded "S" (open-market sale).

Following the transaction, Joyce directly owns 374,531 shares. No derivative securities were bought or sold, and there were no other reportable transactions. The filing involves a single reporting person and indicates direct ownership only.

Positive

Transparent execution under a disclosed Rule 10b5-1 plan, reducing concerns about opportunistic insider trading.
Officer retains 374,531 shares, maintaining significant equity alignment with shareholders.

Negative

Insider share sale of 15,491 shares may be interpreted as modest bearish sentiment despite being pre-planned.

Insights

TL;DR: Small 4% insider sale under 10b5-1 plan; neutral impact on ALHC valuation.

The 15,491-share sale represents roughly 4.1% of Joyce鈥檚 direct holdings. Execution via a pre-approved 10b5-1 plan signals planned diversification rather than an opportunistic move. Post-sale ownership of 374,531 shares keeps the officer materially aligned with shareholders. Size and context point to a neutral read-through for investors.

TL;DR: Transaction follows governance best practices; minimal governance risk.

Disclosure notes the 10b5-1 plan adoption date and provides weighted-average price details, enhancing transparency. No indications of derivative dealings or complex structures. Compliance with Section 16 reporting timelines appears intact. Overall, the filing reflects procedural discipline rather than a governance red flag.

08/01/2025 - 06:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOYCE CHRISTOPHER J

(Last)

(First)

(Middle)

1100 W. TOWN & COUNTRY RD.

SUITE 1600

(Street)

ORANGE

92868

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal and Admin. Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/31/2025		S⁽¹⁾		15,491	D	$16.0061⁽²⁾	374,531	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 11/27/2024

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.00 to $16.01. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce	08/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many ALHC shares did Christopher J. Joyce sell?

He sold 15,491 common shares on 31 Jul 2025.

At what price were the ALHC shares sold?

The weighted-average sale price was $16.0061 per share, within a $16.00-$16.01 range.

Does Joyce still hold ALHC stock after the sale?

Yes. He directly owns 374,531 shares following the transaction.

Was the transaction part of a 10b5-1 trading plan?

Yes. The Form 4 states the sale was executed under a plan adopted on 27 Nov 2024.

Were any derivative securities involved in this filing?

No derivative securities were acquired or disposed of in the reported transaction.

AG真人官方

[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Insights

FAQ

How many ALHC shares did Christopher J. Joyce sell?

At what price were the ALHC shares sold?

Does Joyce still hold ALHC stock after the sale?

Was the transaction part of a 10b5-1 trading plan?

Were any derivative securities involved in this filing?

NASDAQ:ALHC

ALHC Rankings

ALHC Latest News

ALHC Latest SEC Filings

ALHC Stock Data

AG真人官方

Trending News

[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Insights

Financial Analyst neutral

Corporate Governance Expert neutral

FAQ

How many ALHC shares did Christopher J. Joyce sell?

At what price were the ALHC shares sold?

Does Joyce still hold ALHC stock after the sale?

Was the transaction part of a 10b5-1 trading plan?

Were any derivative securities involved in this filing?

NASDAQ:ALHC

ALHC Rankings

ALHC Latest News

ALHC Latest SEC Filings

ALHC Stock Data